---
title: Publications
author: Synn√∏ve Yndestad
date: '2021-06-13'
slug: []
categories: []
tags: []
---


1.	Eikesdal HP, Yndestad S, Elzawahry A, Llop-Guevara A, Gilje B, Blix ES, et al. [Olaparib monotherapy as primary treatment in unselected triple negative breast cancer](https://pubmed.ncbi.nlm.nih.gov/33242536/). Ann Oncol. 2021;32(2):240-9.


2.	Yndestad S, Austreid E, Skaftnesmo KO, Lonning PE, Eikesdal HP. [Divergent Activity of the Pseudogene PTENP1 in ER-Positive and Negative Breast Cancer](https://pubmed.ncbi.nlm.nih.gov/29021233/). Mol Cancer Res. 2018;16(1):78-89.


3.	Yndestad S, Austreid E, Svanberg IR, Knappskog S, Lonning PE, Eikesdal HP. [Activation of Akt characterizes estrogen receptor positive human breast cancers which respond to anthracyclines](https://pubmed.ncbi.nlm.nih.gov/28476032/). Oncotarget. 2017.


4.	Yndestad S, Austreid E, Knappskog S, Chrisanthar R, Lilleng PK, Lonning PE, et al. [High PTEN gene expression is a negative prognostic marker in human primary breast cancers with preserved p53 function](https://pubmed.ncbi.nlm.nih.gov/28213783/). Breast cancer research and treatment. 2017.


5.	Steinskog ES, Sagstad SJ, Wagner M, Karlsen TV, Yang N, Markhus CE, et al. [Impaired lymphatic function accelerates cancer growth](https://pubmed.ncbi.nlm.nih.gov/27329584/). Oncotarget. 2016.


6.	Knappskog S, Berge EO, Chrisanthar R, Geisler S, Staalesen V, Leirvaag B, et al. [Concomitant inactivation of the p53- and pRB- functional pathways predicts resistance to DNA damaging drugs in breast cancer in vivo](https://pubmed.ncbi.nlm.nih.gov/26004085/). Mol Oncol. 2015.


7.	Yndestad S, Eikesdal HP, [PI3K-Akt-mTOR signallering og Anthracyclinresistens](https://onkonytt.no/pi3k-akt-mtor-signalering-og-anthracyklinresistens/). Onkonytt. 2014(1).









